Vitamin D and Heart Health
Observational studies show a strong inverse relationship between serum 25(OH)D and cardiovascular disease. Randomised supplementation trials have been much less encouraging — a pattern that likely reflects reverse causality (people with heart disease spend less time outdoors) rather than a therapeutic gap.
The VITAL trial
VITAL (Manson et al., 2019) is the largest and most authoritative cardiovascular vitamin D trial: 25,871 US adults randomised to 2,000 IU/day cholecalciferol or placebo for 5.3 years. The primary composite endpoint (heart attack, stroke, or cardiovascular death) was not reduced: hazard ratio 0.97, p=0.69. No signal for coronary revascularisation, heart failure, or cardiovascular mortality.
Subgroup analyses hinted at possible benefit in Black participants and those with lower baseline 25(OH)D, but these did not reach conventional significance thresholds. The bottom line for cardiovascular event prevention: vitamin D supplementation does not replace statins, antihypertensives, or lifestyle change.
Blood pressure
Meta-analyses of BP trials show a very small reduction in systolic BP with supplementation (roughly 1–2 mmHg) in vitamin-D–deficient hypertensive patients. In sufficient individuals, no measurable effect. Vitamin D is not a substitute for ACE inhibitors, ARBs, thiazides, or calcium channel blockers.
Vascular calcification
High-dose vitamin D (typically > 4,000 IU/day chronically) combined with high calcium intake theoretically risks arterial calcification, but the human trial evidence for harm at these doses is weak. Vitamin K2 is proposed as protective — see our cofactor page. In practice, keeping cholecalciferol at or below 2,000–4,000 IU/day and getting calcium primarily from food is a sensible cardiovascular-safe strategy.
Heart failure
Small trials (VINDICATE, EVITA) in stable systolic heart failure showed modest improvements in cardiac remodelling markers with 4,000 IU/day cholecalciferol but no change in mortality or hospitalisation. Given that heart failure patients are commonly deficient (limited outdoor time, medication interactions), targeted repletion is reasonable — but not a replacement for guideline-directed medical therapy.
Practical guidance
- Correct deficiency for its own sake — it doesn't reduce your CV event risk directly, but it addresses a common laboratory abnormality with proven benefit for bones, immunity, and muscle.
- Continue all evidence-based cardiovascular care — statins, BP medications, aspirin (where indicated), smoking cessation, Mediterranean-pattern diet, moderate exercise.
- If you're deficient and hypertensive, expect at most a 1–2 mmHg systolic BP reduction from correction.
- Don't take high-dose vitamin D expecting cardiovascular protection — the trials have decisively answered no.